What We're Reading: Page 222
Industry reads hand-picked by our editors
Apr 23, 2019
-
The New York Times
How to Raise a Trillion Dollars
-
Xconomy
Can We Afford to Be Cured? A Conversation With ICER's Steve Pearson
-
Regulatory Focus
How Biopharma Companies Use NIH and Vice Versa
-
Vox
No one knows what Joe Biden thinks about health care
Apr 22, 2019
Apr 18, 2019
Apr 17, 2019
Apr 16, 2019
-
The Wall Street Journal
Health Care, Once a Market Leader, Stumbles in 2019
-
The Washington Post
Unaware he had measles, a man traveled from N.Y. to Michigan, infecting 39 people
-
Task & Purpose
DHS May Classify Fentanyl As A 'Weapon Of Mass Destruction'
Apr 15, 2019
-
Xconomy
How an Ohio Kids' Hospital Quietly Became Ground Zero for Gene Therapy
-
The New York Times
Gene-Edited Babies: What a Chinese Scientist Told an American Mentor
-
STAT
Peter Bach's crazy idea: Give up on biosimilars. Regulate prices instead
-
Financial Times
Purdue tried to buy Reckitt Benckiser’s addiction business
Apr 12, 2019
-
The New York Times
The Scary Shortage of Infectious-Disease Doctors
-
LifeSciVC
Sheer Heart Attack: What Happens When Your Partner Gets Acquired in The Middle of Negotiations
-
BioCentury
Regulatory reprieve with Brexit delay
-
Regulatory Focus
EMA Officials Debate Going Beyond Safe and Effective Determinations for New Drugs
Previous
